ArticleJournal of robotic surgery2026
Robotic liver resection for primary and metastatic hepatobiliary cancer. A decade single-center experience on perioperative and overall survival outcomes.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Robotic liver resection in minimally invasive expert centers is associated with a very low rate of bile leakage: results from a national multicenter cohort.Journal of robotic surgery · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver resection (LR) remains the only potentially curative treatment for primary and secondary hepatobiliary malignancies. Robotic surgery provides technical and short-term clinical advantages over laparoscopy, although concerns regarding oncological and medium/long-term survival outcomes persist. This study examines perioperative outcomes and medium-term oncological survivals of five hepatobiliary malignancies treated with robotic LR (RLR). Between 2013 and 2025, patients undergoing RLR for hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), perihilar cholangiocarcinoma (pCC), Colorectal Liver Metastasis (CRLM), and neuroendocrine tumor metastasis (NET) were consecutively enrolled. Demographic and perioperative variables, including mortality, were retrospectively analyzed. 305 patients were included (CRLM 38.4%, HCC 31.5%, ICC 13.8%, pCC 10.5%, and NET 5.8%). Groups differed significantly in age, comorbidities, and surgical complexity. The HCC group showed the highest Charlson Comorbidity Index (8 [IQR7–9], p < 0.001), while pCC exhibited the greatest operative difficulty according to the Tampa Difficulty Score (37 [IQR25–41], p < 0.001). The median operative time was 296 min [IQR 220–387], and estimated blood loss was 150 mL [IQR 50–300]. The conversion rate was low (1%), and R0-resection resulted 94.1%, although pCC had the highest R1 rate (15.6%). Overall postoperative morbidity was 33.1% and major complications occurred in 12.8%, with both rates highest in pCC (56.2% and 37.5%). 90-day mortality was 3.6% without differences across groups (p = 0.121). 3-years overall survivals for HCC, ICC, pCC, CRLM, and NET were 55.6%, 47.9%, 49.2%, 65.3%, and 90%, respectively. RLR yielded favorable perioperative outcomes with high R0 resection rate across different hepatobiliary malignancies, supporting its expansion and need for larger prospective multicenter studies.
Indexed as
Identifiers
41801582What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.